DBV Technologies Inc.

DBV Technologies completes screening for VITESSE Phase 3 trial, evaluating Viaskin Peanut Patch in peanut-allergic children ages 4-7, with topline results expected by Q4 2025.

A clinical trial involving a wearable skin patch, Viaskin, showed 67% of toddlers with peanut allergies could safely ingest more peanut protein after a year. Led by UCC and DBV Technologies, the trial offers hope for new treatments, as current options are limited and avoidance is challenging. Anaphylaxis occurred in 7.8% of participants.

DBV Technologies announced positive Phase 3 EPITOPE trial results for Viaskin Peanut in peanut-allergic toddlers, showing 67.0% of treated subjects met response criteria vs. 33.5% in placebo. The trial met its primary endpoint with a significant treatment effect (p<0.001) and consistent safety profile. DBV plans further analysis and regulatory exploration for children ages 1 to 3.

A study reveals IgE-producing B cells are enriched in gut tissues, likely from local antibody isotype switching, highlighting the gut's role in food allergy. It suggests a restricted antibody repertoire may mark or predispose to peanut allergy, with implications for diagnostics and therapies.